institute of stem cell research

AG 2: Hematopoiesis > Homepage of Dr. Inge Baas, Md Ph.D.

Back to the overview...

Curriculum Vitae

• 1989 – 1997
  Study in Medical Science, State University Leiden, The Netherlands
  Medical degree with honours
  
  
  • 1991 – 1995
    Student researcher, Department of Pathology, Academic Medical Center and
    University of Amsterdam, Amsterdam, The Netherlands
  • 1992 and 1994
    Student researcher, Department of Gastrointestinal Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    
• 1997 - 1998
  PhD student
  Department of Pathology, Academic Medical Center and
  University of Amsterdam, Amsterdam, The Netherlands
  “Detection and clinical value of dysfunctional p53 protein.”
• 1998 – 2003
  Residency in Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
• 2004 – 2006
  Research Fellow of the Dutch Cancer Society:
  
  
  • 2004:
    Dutch Cancer Institute, Department of Cell Biology, Amsterdam, The Netherlands
  • 2004 - 2005:
    University Medical Center Groningen, Department of Experimental Hematology, Groningen, The Netherlands
  • 2006 - 2007:
    Independent research Group for Hematopoiesis at the Institute of Stem Cell Research, GSF – National Research Center for Environment and Health, Munich, Germany

Fellowships

• 1994:
  Research Grant, Dutch Cancer Society
• 1995:
  Travel award Dutch Heart Foundation
  Travel award Spinoza Foundation, University of Amsterdam
• 1997 – 1998:
  Research Grant NWO Netherlands Organization for Scientific Research
• 2004 – 2006:
  Research Fellowship, Dutch Cancer Society

Publications

• Rozenveld-Geugien M, Baas IO, van Gosliga D, Vellenga E, Schuringa JJ. Expansion of normal and leukemic human hematopoietic stem/progenitor cells requires Rac-mediated interaction with stromal cells.
  Submitted.
• Baas IO , Marijt WAF, Barge RMY, Starrenburg IC, Willemze R, Falkenburg JHF. Hematopoietic chimerism status may predict relapse after in vitro T-cell depleted allogeneic stem cell transplantation for acute leukaemia.
  Manuscript in preparation.
• Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen – Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH. (2004)
  Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
  Biol. Blood Marrow Transplant 10: 204-212.
• Koopmans RP, Baas IO, Schreuder MCJ, Hart W. (2000)
  Klinisch denken en beslissen in de praktijk. Een patient met aanhoudende koorts. NTvG 144: 1480-1484
• Michels A, Baas IO, Schreuder MCJ, Kuyper EJ. (1999)
  Reizigersdiarrhee met het nieuwe serotype Vibrio Cholerae O139 Bengalen.
  NT Med Microb 2: 38-40
• Baas IO , Hruban HR, Offerhaus GJA. (1999)
  Clinical applications of detecting dysfunctional p53 tumor suppressor protein.
  Histol Histopathol 14: 279-284
• Baas IO , van Rees BP, Musler A, Craanen ME, Tytgat GN, van den Berg FM, Offerhaus GJA. (1998)
  Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach.
  J Clin Pathol 51: 662-666
• Sturm PD, Baas IO, Clement MJ, Nakeeb A, Offerhaus GJA, Hruban HR, Pitt H. (1998)
  Alterations of the p53 tumor suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area.
  Int J Cancer 78: 695-698
• Slebos RJ, Baas IO, Clement MJ, Offerhaus GJA, Askin FB, Hruban HR, Westra WH. (1998)
  p53 alterations in atypical alveolar hyperplasia of the human lung.
  Hum Pathol 29: 801-808
• Baas IO , Offerhaus GJA, Hruban HR. (1997)
  Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease.
  Clin Microbiol Infect 3: 393-395
• Slebos RJ, Baas IO, Clement MJ, Polak MM, Mulder JW, van den Berg FM, Hamilton SR, Offerhaus GJA. (1996)
  Clinical and pathological association with p53 tumour suppressor gene mutations and expression of p21 WAF1/CIP1 in colorectal carcinoma.
  Br J Cancer 74: 165-171
• Westra WH, Baas IO, Hruban HR, Askin FB, Wilson K, Offerhaus GJA, Slebos RJ. (1996)
  K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56: 2224-2228
• Baas IO , Offerhaus GJA, El-Deiry WS, Wu TC, Hutchins GM, Kasper EK, Baughman KL, Baumgartner WA, Chiou CJ, Hayward GS, Hruban HR. (1996)
  The WAF1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients.
  Hum Pathol 27: 324-329
• Baas IO , van den Berg FM, Mulder JWR, Clement MJ, Slebos RJ, Hamilton SR, Offerhaus GJA. (1996)
  Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms.
  J Pathol 178: 264-267
• Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJA. (1995)
  Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma.
  Br J Cancer 71: 1257-1262
• Offerhaus GJA, Baas IO. (1994)
  Moleculair-genetische aanknopingspunten voor preventie en behandeling van colorectum carcinoom.
  NTvG 138: 561-564
• Baas IO , Mulder JW, Offerhaus GJA, Vogelstein B, Hamilton SR. (1994)
  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.
  J Pathol 172: 5-12
• Westra WH, Offerhaus GJA, Goodman SN, Slebos RJ, Polak MM, Baas IO, Rodenhuis S, Hruban RH. (1993)
  Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking.
  Am J Surg Pathol 17: 213-220
• van den Berg FM, Baas IO, Polak MM, Offerhaus GJA. (1993)
  Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid.
  Am J Pathol 142: 381-385